Table 1.
Patient characteristics
Group 1 4 L to 2 L/h |
Group 2 2 L to 4 L/h |
||||
---|---|---|---|---|---|
n = 7 | N = 7 | ||||
Age (years) | 65 | (38-69) | 65 | (60-75) | |
Male/female (n) | 5/2 | 5/2 | |||
Body weight (kg) | 75 | (72-80) | 75 | (60-98) | |
Cause of ARF (n) | |||||
sepsis | 5 | 5 | |||
cardiogenic shock | 2 | 1 | |||
liver failure | 1 | ||||
APACHE II | 35 | (29-38) | 25 | (19-31) 0.07 | |
APACHE II predicted mortality (%) | 85 | (72-88) | 56 | (21-73) 0.10 | |
APACHE III | 128 | (104-138) | 94 | (50-148) | 0.18 |
SOFA start CVVH | 14 | (11-15) | 9 | (5-9) | 0.004 |
Hemoglobin (mmol/L) | 5.7 | (4.8-6.5) | 5.8 | (5.6-6.1) | |
Hematocrit | 0.29 | (0.25-0.30) | 0.28 | (0.26-0.30) | |
PTT (sec) | 11.8 | (10.8-14.5) | 11.4 | (11.1-12.7) | 0.95 |
aPTT (sec) | 32.3 | (25.5-36.7) | 28.2 | (20.3-41.7) | 0.57 |
Antithrombin (%) | 79 | (43-86) | 46 | (17-64) | 0.23 |
Platelet count (109/L) | 182 | (163-286) | 139 | (96-221) | 0.26 |
Anti-Xa activity (IU) | 0.11 | (0.00-0.55) | 0.01 | (0.00-0.15) | 0.30 |
ETPTlag (sec) | 23.0 | (18.6-31.0) | 19.7 | (14.3-22.1) | 0.13 |
ETPTmax (sec) | 53.1 | (46.0-81.4) | 52.7 | (46.1-54.9) | 0.80 |
ETPCmax (mA/min) | 108 | (91-125) | 114 | (75-153) | 0.48 |
ETPAUC (mA) | 275 | (137-379) | 341 | (223-401) | 0.54 |
F1+2 (pmol/L) | 313 | (158-689) | 216 | (156-288) | 0.32 |
TAT (μg/L) | 20.7 | (4.8-28.9) | 8.3 | (6.7-10.5) | 0.18 |
D-dimers (μg/ml) | 14.2 | (7.6-43.8) | 4.1 | (1.5-29.8) | 0.25 |
Creatinine (μmol/L) | 297 | (221-453) | 251 | (141-329) | 0.54 |
Urea (mmol/L) | 34 | (15-49) | 36 | (10-47) | 0.81 |
RIFLE score | 3 | 3 | 1.0 |
Values in median (interquartile range) unless indicated differently.
APACHE = Acute Physiology and Chronic Health Evaluation; aPTT = activated thromboplastin time; CVVH = continuous venovenous hemofiltration; ETP = endogenous thrombin potential; ETPAUC = area under the curve of the thrombin generation curve; ETPCmax = maximal activity of ETP; ETPTlag = ETP lag time = ETPTmax = time to max ETP activity; F1+2 = prothrombin fragment; PTT = prothrombin time; SOFA = Sequential Organ Failure Assessment; TAT = thrombin-antithrombin complexes.
RIFLE = Risk = 1, Injury = 2, Failure = 3.